Request Demo
Recent blog posts
Latest Hotspot
8 min read
CTR20262132 QY-201 Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262132 clinical trial report covering QY-201, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262104 Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262104 clinical trial report covering Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate, Phase 3, endpoints, sponsor, geography, readout
Latest Hotspot
8 min read
NCT07640789 Izalontamab Brengitecan Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640789 clinical trial report covering Izalontamab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07642050 BHV-1400 Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07642050 clinical trial report covering BHV-1400, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07641946 Tranexamic Acid Hemoptysis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641946 clinical trial report covering Tranexamic Acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126603 Becotatug vedotin Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126603 clinical trial report covering Becotatug vedotin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2011260018 Paclitaxel Hirschsprung Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2011260018 clinical trial report covering Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07644052 Gabapentin/Nabilone Marijuana Abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644052 clinical trial report covering Gabapentin/Nabilone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645833 Eptinezumab-JJMR Pseudotumor Cerebri Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645833 clinical trial report covering Eptinezumab-JJMR, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645924 Elismetrep Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645924 clinical trial report covering Elismetrep, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645248 Tetrafluoroethane Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645248 clinical trial report covering Tetrafluoroethane, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260042 HP-6050 Psychomotor Agitation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2071260042 clinical trial report covering HP-6050, Phase 3, endpoints, sponsor, geography, readout timing and development white space.